Edition:
United Kingdom

Verona Pharma PLC (VRNA.OQ)

VRNA.OQ on NASDAQ Stock Exchange Global Market

16.12USD
18 May 2018
Change (% chg)

$0.12 (+0.75%)
Prev Close
$16.00
Open
$16.12
Day's High
$16.12
Day's Low
$16.12
Volume
100
Avg. Vol
1,740
52-wk High
$25.01
52-wk Low
$10.44

Chart for

About

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a... (more)

Overall

Beta: 1.05
Market Cap(Mil.): £149.65
Shares Outstanding(Mil.): 105.02
Dividend: --
Yield (%): --

Financials

  VRNA.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.15 -- --
ROI: -17.35 1.57 14.38
ROE: -17.50 2.43 16.07

BRIEF-Verona Pharma Files For Mixed Shelf Of Upto $200 Mln

* VERONA PHARMA PLC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: (https://bit.ly/2rZgygq) Further company coverage:

22 May 2018

BRIEF-Verona Pharma Says Positive Top-Line Data From Phase 2B Trial Of RPl554

* VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2B CLINICAL TRIAL OF RPL554 FOR MAINTENANCE TREATMENT OF COPD

26 Mar 2018

BRIEF-Verona Pharma Says Positive Top-Line Data From Phase 2A Trial With Rpl554

* ‍REG-VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2A TRIAL WITH RPL554 IN CYSTIC FIBROSIS PATIENTS​

02 Mar 2018

BRIEF-Verona Pharma Expects To Report Top-Line Data From Phase 2b Trial Of Nebulized RPl554​ Early In Q2

* VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2B TRIAL EARLY IN Q2 OF 2018 FOR NEBULIZED RPL554​

13 Feb 2018

Earnings vs. Estimates